Heart failure after treatment for breast cancer

We aimed to develop dose–response relationships for heart failure (HF) following radiation and anthracyclines in breast cancer treatment, and to assess HF associations with trastuzumab and endocrine therapies.

[1]  S. Darby,et al.  Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer , 2018, British Journal of Cancer.

[2]  F. Girolami,et al.  Comparison of long‐term outcome in anthracycline‐related versus idiopathic dilated cardiomyopathy: a single centre experience , 2018, European journal of heart failure.

[3]  S. Darby,et al.  Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines among 19,464 breast cancer patients in Denmark, 1977–2005 , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  Michael Hauptmann,et al.  Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. , 2017, Blood.

[5]  K. Bailey,et al.  Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer , 2017, Circulation.

[6]  J. Bergh,et al.  Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  L. Tarantini,et al.  Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients , 2017, Clinical breast cancer.

[8]  R. Chlebowski,et al.  Cardiovascular Disease After Aromatase Inhibitor Use. , 2016, JAMA oncology.

[9]  P. Austin,et al.  Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Jeroen J. Bax,et al.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines , 2016, European journal of heart failure.

[11]  G. Lip,et al.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). , 2016, European heart journal.

[12]  E. Perez,et al.  Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Rietveld,et al.  Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors. , 2016, International journal of radiation oncology, biology, physics.

[14]  Zhe Wang,et al.  Exposure of the Heart in Breast Cancer Radiation Therapy: A Systematic Review of Heart Doses Published During 2003 to 2013. , 2015, International journal of radiation oncology, biology, physics.

[15]  G. Curigliano,et al.  Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy , 2015, Circulation.

[16]  M. Dowsett,et al.  Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Hall,et al.  Risk of ischemic heart disease in women after radiotherapy for breast cancer. , 2013, The New England journal of medicine.

[18]  C. Geyer,et al.  Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Allen,et al.  Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study , 2012, Journal of the National Cancer Institute.

[20]  L. Moja,et al.  Trastuzumab containing regimens for early breast cancer. , 2012, The Cochrane database of systematic reviews.

[21]  Jong-Hyeon Jeong,et al.  Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Hall,et al.  Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  S. Martino,et al.  Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Goodwin,et al.  Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Gianni,et al.  Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes , 2007, Cardiovascular Toxicology.

[26]  H. Bartelink,et al.  Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. , 2007, Journal of the National Cancer Institute.

[27]  S. Hancock,et al.  Diastolic dysfunction after mediastinal irradiation. , 2005, American heart journal.

[28]  J. Goodwin,et al.  Cardiac morbidity of adjuvant radiotherapy for breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Plummer.  Improved estimates of floating absolute risk , 2004, Statistics in medicine.

[30]  J. Hainsworth,et al.  Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. , 2013, The Lancet. Oncology.